{"nctId":"NCT00152009","briefTitle":"Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17","startDateStruct":{"date":"2003-01-29","type":"ACTUAL"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"count":345,"armGroups":[{"label":"SPD503 (Guanfacine HCl) (2 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (Guanfacine hydrochloride) (2 mg)"]},{"label":"SPD503 (3 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (3 mg)"]},{"label":"SPD503 (4 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: SPD503 (4 mg)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SPD503 (Guanfacine hydrochloride) (2 mg)","otherNames":[]},{"name":"SPD503 (3 mg)","otherNames":[]},{"name":"SPD503 (4 mg)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a primary diagnosis of ADHD\n* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements\n\nExclusion Criteria:\n\n* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms\n* History of seizure during the last 2 years\n* Subject has any specific cardiac condition or family history of significant cardiac condition\n* Subject is pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at Up to 5 Weeks","description":"Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.93","spread":"1.37"},{"groupId":"OG001","value":"-16.03","spread":"1.38"},{"groupId":"OG002","value":"-18.51","spread":"1.39"},{"groupId":"OG003","value":"-8.51","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Score at Up to 5 Weeks","description":"The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) reflecting no symptoms to 3 (very much true) reflecting severe symptoms with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.59","spread":"1.86"},{"groupId":"OG001","value":"-15.43","spread":"1.95"},{"groupId":"OG002","value":"-21.49","spread":"2.00"},{"groupId":"OG003","value":"-8.66","spread":"1.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Conner's Teacher Rating Scale-revised Short Version (CTRS-R) Score at Up to 5 Weeks","description":"The Conner's Teacher Rating Scale-revised short version (CTRS-R) consists of 28 questions graded on a scale from 0 (not true at all) reflecting no symptoms to 3 (very much true) reflecting severe symptoms with a total score ranging from 0 to 84. Higher scores are indicative of increased ADHD. This scale allows teachers to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.02","spread":"1.69"},{"groupId":"OG001","value":"-14.88","spread":"1.79"},{"groupId":"OG002","value":"-15.26","spread":"1.80"},{"groupId":"OG003","value":"-2.17","spread":"1.70"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Clinical Global Impression-Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"45","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Parent Global Assessment (PGA)","description":"Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Score at 5 Weeks","description":"The Child Health Questionnaire-Parent Form (CHQ-PF50) was developed to measure the physical and psychosocial well-being of children aged 5 years of age and older. Total score ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.03","spread":"1.22"},{"groupId":"OG001","value":"9.01","spread":"1.20"},{"groupId":"OG002","value":"10.64","spread":"1.32"},{"groupId":"OG003","value":"5.72","spread":"1.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.84"},{"groupId":"OG001","value":"-1.82","spread":"0.84"},{"groupId":"OG002","value":"-2.13","spread":"0.92"},{"groupId":"OG003","value":"-0.18","spread":"0.86"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":87},"commonTop":["Headache","Somnolence","Fatigue","Abdominal pain upper","Sedation"]}}}